Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs were updated Aug. 1, 2025:

Effective Sept. 1, 2025:

• Biologic Immunomodulators
• Cibinqo
• Efgartigimod
• Endari
• Eohilia
• Filspari
• Hympavzi
• IL-4 Inhibitors
• IL-13 Antagonist
• IL-31 Inhibitor
• Oral Anticoagulant
• Otezla
• Qfitlia
• Tavneos
• Vykat XR

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of the prior authorization page of our website.

If you have any questions, please contact your BCBSKS provider relations representative.